
News|Articles|December 10, 2012
FDA expands Zytiga's use for late-stage prostate cancer
FDA expanded the approved use of abiraterone acetate (Zytiga, Jannsen Bioech) to treat men with late-stage castration-resistant prostate cancer prior to receiving chemotherapy.
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
7 things you need to know about the PBM reforms signed into law this week
2
PBM reform. It has finally happened
3
TrumpRx launches; some experts question its long-term value
4
FDA issues draft guidance on MRD and complete response as primary endpoints for accelerated multiple myeloma drug approvals
5

























